Mechanism of isorhamnetin in alleviating acute lung injury by regulating pyroptosis medicated by NLRP3/ASC/caspase-1 axis.
10.19540/j.cnki.cjcmm.20250409.702
- Author:
Ya-Lei SUN
1
;
Yu GUO
1
;
Xin-Yu WANG
1
;
Ya-Su ZHANG
1
;
Xue CHENG
1
;
Ke ZHU
1
;
Li-Dian CHEN
1
;
Xiao-Dong FENG
1
Author Information
1. Rehabilitation Medicine College, Henan University of Chinese Medicine Zhengzhou 450046, China.
- Publication Type:Journal Article
- Keywords:
NLRP3/ASC/caspase-1 axis;
acute lung injury;
isorhamnetin;
macrophage;
pyroptosis
- MeSH:
Animals;
Pyroptosis/drug effects*;
NLR Family, Pyrin Domain-Containing 3 Protein/genetics*;
Acute Lung Injury/physiopathology*;
Mice;
Mice, Inbred BALB C;
Quercetin/pharmacology*;
Caspase 1/genetics*;
CARD Signaling Adaptor Proteins/genetics*;
Male;
RAW 264.7 Cells;
Humans;
Lung/metabolism*
- From:
China Journal of Chinese Materia Medica
2025;50(15):4120-4128
- CountryChina
- Language:Chinese
-
Abstract:
This study aims to explore the intervention effects of isorhamnetin(Isor) on acute lung injury(ALI) and its regulatory effects on pyroptosis mediated by the NOD-like receptor family pyrin domain containing 3(NLRP3)/apoptosis-associated speck-like protein containing a CARD(ASC)/cysteine aspartate-specific protease-1(caspase-1) axis. In the in vivo experiments, 60 BALB/c mice were divided into five groups. Except for the control group, the other groups were administered Isor by gavage 1 hour before intratracheal instillation of LPS to induce ALI, and tissues were collected after 12 hours. In the in vitro experiments, RAW264.7 cells were divided into five groups. Except for the control group, the other groups were pretreated with Isor for 2 hours before LPS stimulation and subsequent assessments. Hematoxylin-eosin(HE) staining was used to observe pathological changes in lung tissue, while lung swelling, protein levels in bronchoalveolar lavage fluid(BALF), and myeloperoxidase(MPO) levels in lung tissue were measured. Cell proliferation toxicity and viability were assessed using the cell counting kit-8(CCK-8) method. Enzyme-linked immunosorbent assay(ELISA) was used to detect the levels of interleukin-1β(IL-1β), IL-6, IL-18, and tumor necrosis factor-α(TNF-α). Protein levels of NLRP3, ASC, cleaved caspase-1, and the N-terminal fragment of gasdermin D(GSDMD-N) were evaluated using immunohistochemistry, immunofluorescence, and Western blot. The results showed that in the in vivo experiments, Isor significantly improved pathological damage in lung tissue, reduced lung swelling, protein levels in BALF, MPO levels in lung tissue, and levels of inflammatory cytokines such as IL-1β, IL-6, IL-18, and TNF-α, and inhibited the high expression of the NLRP3/ASC/caspase-1 axis and the pyroptosis core gene GSDMD-N. In the in vitro experiments, the safe dose of Isor was determined through cell proliferation toxicity assays. Isor reduced cell death and inhibited the expression levels of the NLRP3/ASC/caspase-1 axis, GSDMD-N, and inflammatory cytokines. In conclusion, Isor may alleviate ALI by modulating pyroptosis mediated by the NLRP3/ASC/caspase-1 axis.
